Cover Image

Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma

Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is...

Full description

Saved in:
Bibliographic Details
Main Authors: Trojan, Andreas (Author) , Tinguely, Marianne (Author) , Vallet, Sonia (Author) , Seifert, Burkhardt (Author) , Jenni, Bettina (Author) , Zippelius, Alfred (Author) , Witzens-Harig, Mathias (Author) , Mechtersheimer, Gunhild (Author) , Ho, Anthony Dick (Author) , Goldschmidt, Hartmut (Author) , Jäger, Dirk (Author) , Boccadoro, Mario (Author) , Ladetto, Marco (Author)
Format: Article (Journal)
Language:English
Published: [2006]
In: Swiss medical weekly
Year: 2006, Volume: 136, Issue: 25/26, Pages: 400-403
ISSN:1424-3997
Online Access:Verlag, lizenzpflichtig, Volltext: https://serval.unil.ch/resource/serval:BIB_F68233E85238.P001/REF
Get full text
Author Notes:Andreas Trojan, Marianne Tinguely, Sonia Vallet, Burkhardt Seifert, Bettina Jenni, Alfred Zippelius, Mathias Witzens-Harig, Gunhild Mechtersheimer, Anthony D. Ho, Hartmut Goldschmidt, Dirk Jäger, Mario Boccadoro, Marco Ladetto
Description
Summary:Several biological and clinical considerations suggest the involvement of cyclooxygenase-2 (COX-2), the key enzyme of prostaglandin (PG) synthesis, in the pathogenesis and progression of haematological malignancies. Despite the wealth of data concerning COX-2 expression, only limited information is available on multiple myeloma (MM). Using standard immunohistochemistry we therefore evaluated COX-2 protein expression in samples from 57 patients with a primary diagnosis of MM. Time to progression and a variety of clinicopathological features were evaluated by the Kaplan-Meier method and the Cox regression model. In addition, COX-2 expression was evaluated by staining bone marrow from healthy donors and 11 patients with MGUS. Overall, 31 MM samples (54%) expressed COX-2. Positivity for COX-2 was unrelated to stage or clinical or molecular features of the disease. However, patients with COX-2 positive tumours experienced a significantly shorter time to progression (17 vs 30 months, p = 0.037). In summary, COX-2 is frequently expressed in MM and correlates with shorter progression-free survival.
Item Description:Gesehen am 15.02.2022
Physical Description:Online Resource
ISSN:1424-3997

Similar Items